The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
MrA..
It is not just cancer.. Multiple partnerships are cooking (e.g. LG chem) that are nearing readiness.
Not long to wait now and the AffiDX revenue will see us through to conclusion of these deals (e.g LG chem payments)
For Avacta (AND ITS SHAREHOLDERS) to be self funded from here is HUGE!
Ignore the trolls.
It is highly probable, even at the lowest level revenue estimates, that Avacta will be self funded until they deliver the big deal (s).
As a long term hold I don't see many better r/r than avacta
Between the rns and the comments from the previous webinar.
The previous webinar acted as a revenue warning/correction e.g. Market had moved, margins were tight and we would scale supply for confirmed demand..
This rns clearly corrects previous guidance given during the webinar. As a LTH, I'm delighted by the rns today as it clarifies that AFFIDX remains a big deal.
"Manufacturing scale up continues to progress well and we remain focused on the challenge of being able to supply the clear demand in the market.
"We continue to see significant levels of commercial interest from around the world and are progressing a number of opportunities in a range of sectors. I look forward to updating the market on further developments."
China about to test entire population of Wuhan (11m) after 300 cases detected.
The next Covid variant could kill up to one in THREE people: SAGE warns
scenario is 'realistic possibility' and UK's vaccine roll-out may even speed up mutant strain's emergence
https://www.dailymail.co.uk/news/article-9844701/SAGE-Covid-variant-kill-one-three-people.html
I would be curious to know if the TT for the AffiDX GAD / MOL DESIGNED/Developed LFT could be complete already and ready to be manufactured by ODX?
AS said that GAD were already in an advanced state of manufacture for the final affidx test.
Only a few weeks back AS was guiding the market that there remained a possibility of 30m volumes utilising the UK GOV installed capacity.
For AS to state this I would think that the discussions must have been very active.
The redesign now opens the door widely enabling AffiDX to be selected
AS has refrained from criticising PE / DHSC publicly (why?) and has guided the market that Avacta remain in the procurement process and active in discussions. Couple this with the latest redesign of the qualification guidelines and I think the probability that the redesign is designed to support Avacta is high! Very High!!
I wonder if Soros and Gates have lobbied this latest DHSC change??
Avacta will be ahead of the curve here as have been discussing these very changes with UK Gov for months
Actually clinical samples should now be well in excess of the desired requirements.
I expect that Avacta will be running an independent large scale (10k samples) validation which will blow all competition out of the water for good.
It's also in the rns...
Strong day ahead I think. Thursday close and Friday action suggested a leak.
What would be the value of the animal health business should they stick a for sale sign up?
Who and for what use are these affimers being purchased?
General description
Ubiquitin (Ub), a highly conserved 76-amino acid (8.6 kDa) protein that escorts proteins for rapid degradation to the multi-component enzymatic complex known as the 26S proteasome. Ubiquitin is initially produced as polyubiquitin-B or polyubiquitin-C precursor protein and its posttranslational cleavage yield multiple copies of identical 76-amino acid ubiquitin. Ubiquitin is involved in one of the most common post-translational modifications of cellular proteins, where it is linked covalently via its carboxyl terminus (Gly76) to lysine residues in target proteins. A given target lysine residue can be linked to one single ubiquitin molecule (monoubiquitylated) or to a chain of ubiquitins (polyubiquitylated). In a polyubiquitin chain, ubiquitin molecules can be linked through one of the seven lysine residues (K6, K11, K27, K29, K33, K48, and K63) or through the ubiquitin N-terminus methionine 1 residue (which generates linear chains). Polyubiquitin chains, when attached to a target protein, have different functions depending on the Lys residue of the ubiquitin that is linked: Lysine 6-linked may be involved in DNA repair; Lysine 11-linked is involved in endoplasmic reticulum-associated degradation, lysine 29-linked is involved in lysosomal degradation, and Lysine 48-linked is involved in protein degradation via the proteasome. Affimer molecules are small proteins (~ 12 kDa) that bind to target molecules with similar specificity and affinity to that of antibodies. These engineered non-antibody binding proteins are designed to mimic the molecular recognition characteristics of monoclonal antibodies in different applications. It has been shown that each affimer molecule ca bind one ubiquitin molecule and the Affimer dimerizes to bind the two ubiquitin moieties of a diubiquitin in a linkage-specific manner. The K6 Affimer is reported to tightly bind to K6 diubiquitin in a highly specific manner. It can be used to detect K6 chains and with polyubiquitin enrichment it can detect even the endogenous levels of K6 chains. (Ref.: Michel, MA., et al. (2017). Mol. Cell. 68(1); 233-246).
Specificity
Anti-diUbiquitin K6 GFP/His-tag Affimer reagent detects K6 linked poly-ubiquitin chains with a KD of approximately 20 pM. Binding to other di-ubiquitin linkages is negligible.
Immunogen
Ubiquitin Lys6 specific Affimer reagent, Anti-Ubiquitin Lys6 specific Affimer reagent, Ubiquitin Lys6 specific Affimer Reagent GFP/His tag
Application
Quality Control Testing
Evaluated by Western Blotting with Various K-linked di-ubiquitin chains.
Western Blotting Analysis (WB): A 1:1,000 dilution of this Affimer reagent detected di-ubiquitin K6-linkages.
Tested Applications
Western Blotting Analysis: A representative lot of this Affimer detected di-Ubiquitin Lys6. in Western Blotting applications (Michel, M.A., et. al. (2017). Mol Cell. 68(1):233-246).
Do you have a link? If the below is true the vaccine would not have been approved for use it is that bad.
Israel says Pfizer vaccine effectiveness down to 39% with Delta.
At this level and the strength going into close yesterday looks to be in place again now.
Interesting!
If Ava6000 was given to first patient on July 16th....and that patient feels well after receiving the chemo, you have your first indication that all could be going according to plan
80 participants!!!
Is it a leak of some sort?